JP2012516879A5 - - Google Patents

Info

Publication number

JP2012516879A5

JP2012516879A5 JP2011548731A JP2011548731A JP2012516879A5 JP 2012516879 A5 JP2012516879 A5 JP 2012516879A5 JP 2011548731 A JP2011548731 A JP 2011548731A JP 2011548731 A JP2011548731 A JP 2011548731A JP 2012516879 A5 JP2012516879 A5 JP 2012516879A5

Authority

JP

Japan

Prior art keywords

cyclodextrin

tgf

pharmaceutical composition

composition according

amount

Prior art date

2010-02-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 229920000858 Cyclodextrin Polymers 0.000 claims 16
• 239000008194 pharmaceutical composition Substances 0.000 claims 11
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 9
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 9
• 108090000765 processed proteins & peptides Proteins 0.000 claims 9
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 9
• 239000003112 inhibitor Substances 0.000 claims 7
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 5
• 229940008099 dimethicone Drugs 0.000 claims 5
• 239000004205 dimethyl polysiloxane Substances 0.000 claims 5
• 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 5
• 239000000839 emulsion Substances 0.000 claims 5
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 5
• 229960004853 betadex Drugs 0.000 claims 4
• 239000001116 FEMA 4028 Substances 0.000 claims 3
• 235000011175 beta-cyclodextrine Nutrition 0.000 claims 3
• GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 3
• 229940080345 gamma-cyclodextrin Drugs 0.000 claims 3
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 230000001404 mediated effect Effects 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 150000003839 salts Chemical class 0.000 claims 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000002480 mineral oil Substances 0.000 claims 1
• 235000010446 mineral oil Nutrition 0.000 claims 1
• 229920001296 polysiloxane Polymers 0.000 claims 1
• 239000003755 preservative agent Substances 0.000 claims 1
• 230000002335 preservative effect Effects 0.000 claims 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1